Clinical improvement and multimodal regulatory effects of Hsp90 inhibition on, e.g., cell signaling, proinflammatory cytokine secretion, dsDNA antibodies, proteinuria, or lymphocytes activity (e.g., expansion of Treg or reduction in pathogenic T and B cell lineage populations) in SLE was revealed using experimental animal models. Here, HSP90AB1 is linked to systemic lupus erythematosus.